Workflow
Touchstone International Medical Science (688013)
icon
Search documents
天臣医疗(688013) - 2021 Q1 - 季度财报
2021-04-29 16:00
Financial Performance - Operating revenue for Q1 2021 reached CNY 45.83 million, a 50.05% increase year-on-year[6] - Net profit attributable to shareholders was CNY 12.94 million, up 115.39% from the same period last year[6] - Basic and diluted earnings per share were both CNY 0.16, representing a 60.00% increase year-on-year[6] - Total revenue for Q1 2021 was ¥45,832,956.17, representing a 50.05% increase compared to ¥30,544,697.75 in Q1 2020, driven by sales growth[16] - Net profit for Q1 2021 was ¥12,939,825.97, representing a 115.0% increase compared to ¥6,007,755.22 in Q1 2020[30] - Operating profit for Q1 2021 was ¥14,605,126.27, an increase of 158.5% from ¥5,654,185.42 in Q1 2020[30] - The total comprehensive income for Q1 2021 was ¥13,032,248.48, an increase of 116.9% from ¥6,008,190.92 in Q1 2020[31] Assets and Liabilities - Total assets increased by 3.99% to CNY 504.62 million compared to the end of the previous year[6] - The company’s total assets as of March 31, 2021, included trading financial assets of ¥337,632,905.48, an increase of 33.69% from the previous period[16] - Total assets increased to CNY 504,619,932.96 as of March 31, 2021, up from CNY 485,243,095.67 at the end of 2020, representing a growth of approximately 2.8%[20] - Total liabilities rose to CNY 25,695,037.63 from CNY 19,350,448.82, marking an increase of about 32.9%[22] - The company reported a significant increase in accounts payable, which rose to CNY 10,127,687.22 from CNY 3,065,594.77, an increase of approximately 230.5%[21] Cash Flow - Cash flow from operating activities was CNY 14.81 million, a significant increase of 773.31% compared to the previous year[6] - The net cash flow from operating activities increased significantly by 773.31% to ¥14,809,824.12, attributed to higher sales revenue[17] - In Q1 2021, the company generated cash inflow from operating activities amounting to ¥52,909,258.30, a 51.8% increase from ¥34,868,177.35 in Q1 2020[34] - The company reported cash inflow from investment activities of ¥172,891,736.75 in Q1 2021, compared to only ¥2,215,353.22 in Q1 2020, indicating a substantial increase[35] - The company experienced a net decrease in cash and cash equivalents of ¥68,145,484.17 in Q1 2021, compared to a decrease of ¥2,877,598.86 in Q1 2020[35] Research and Development - R&D expenses amounted to CNY 3.78 million, a 15.37% increase year-on-year, with R&D investment accounting for 8.24% of operating revenue[8] - Research and development expenses for Q1 2021 totaled ¥3,775,416.79, up 15.4% from ¥3,272,532.68 in Q1 2020[29] Shareholder Information - The company had a total of 4,537 shareholders at the end of the reporting period[12] - The top two shareholders, Chen Wangyu and Chen Wangdong, held 26.22% and 26.17% of shares, respectively[12]
天臣医疗(688013) - 2020 Q3 - 季度财报
2020-10-26 16:00
Financial Performance - Operating revenue for the first nine months decreased by 9.28% year-on-year, amounting to RMB 118,834,772.00[7] - Net profit attributable to shareholders decreased by 24.67% year-on-year, totaling RMB 26,072,007.42[7] - Basic and diluted earnings per share decreased by 25.86% to RMB 0.43[7] - Total profit for the first three quarters of 2020 was ¥30,079,904.22, a decline of 25.0% from ¥40,059,161.37 in the same period of 2019[28] - Net profit for Q3 2020 was ¥9,780,901.98, down 25.5% from ¥13,137,991.40 in Q3 2019[28] - The net profit for Q3 2020 was CNY 12,137,105.03, a decrease from CNY 13,099,014.95 in Q3 2019, representing a decline of approximately 7.4%[31] - The total profit for Q3 2020 was CNY 13,847,397.17, down from CNY 15,352,285.40 in Q3 2019, reflecting a decrease of about 9.8%[31] Asset and Equity Growth - Total assets increased by 287.03% year-on-year, reaching RMB 483,420,019.53[7] - Net assets attributable to shareholders increased by 326.40% year-on-year, totaling RMB 457,032,276.90[7] - Owner's equity surged to ¥457,032,276.90 compared to ¥107,184,821.57, marking a significant increase of approximately 326.5%[20] - Total assets increased to ¥483,420,019.53 from ¥124,905,957.67, representing a growth of approximately 286.5% year-over-year[19] - Cash and cash equivalents reached ¥263,505,445.67, up from ¥14,432,651.40, indicating a growth of approximately 1,726.5%[22] Cash Flow and Financing Activities - The company reported a net cash flow from operating activities of RMB 29,880,847.63, an increase of 11.69% year-on-year[7] - The company’s net cash flow from financing activities was ¥326,566,200.00, a significant recovery from a negative cash flow of -¥29,747,303.00 in the previous year[15] - The company raised CNY 342,794,200.00 through financing activities in Q3 2020, a significant increase compared to CNY 15,000,000.00 in Q3 2019[35] - Cash flow from operating activities for Q3 2020 was CNY 29,880,847.63, an increase from CNY 26,754,533.51 in Q3 2019, showing a growth of about 8.0%[34] Research and Development - The proportion of R&D investment to operating revenue increased by 1.02 percentage points to 8.51%[8] - Research and development expenses for Q3 2020 were ¥3,924,168.44, an increase of 14.8% compared to ¥3,417,491.60 in Q3 2019[27] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[47] Shareholder Information - The total number of shareholders reached 9,093 by the end of the reporting period[10] - The top two shareholders, Chen Wangyu and Chen Wangdong, each hold 26.17% of the shares, totaling 20,934,000 shares[10] Liabilities and Current Assets - Total liabilities increased to ¥10,233,985.17, a 166.36% rise from ¥3,842,222.71, mainly due to accrued but unpaid IPO issuance costs[13] - Current liabilities rose to ¥25,637,742.63 from ¥16,641,549.87, an increase of about 54.8%[19] - Total current assets reached ¥408,191,607.67, a substantial increase from ¥49,449,071.50, indicating strong liquidity[18] Inventory and Other Assets - Inventory increased to ¥24,038,613.19 from ¥23,466,724.30, a rise of about 2.4%[23] - The company reported a total non-current asset value of ¥75,228,411.86, slightly down from ¥75,456,886.17, a decrease of about 0.3%[19] - The company reported a significant inventory level of 23,466,724.30, indicating potential for future sales[44]